BAR­DA bets $483M on Mod­er­na’s Covid-19 vac­cine as the biotech plots ul­tra-fast PhI­II, re­cruit­ing 150 staffers to scale up 24/7

BAR­DA has agreed to gam­ble up to $483 mil­lion on Mod­er­na’s clin­i­cal-stage vac­cine to guard against SARS-CoV-2 — a move that will fund de­vel­op­ment through a hoped-for BLA fil­ing for ac­cel­er­at­ed ap­proval while open­ing the door to a piv­otal study as ear­ly as the fall of this year. And the biotech is launch­ing a re­cruit­ment cam­paign to hire 150 staffers to ramp up a 24/7 sched­ule on man­u­fac­tur­ing de­signed to quick­ly scale up to tens of mil­lions of dos­es.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER